IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy

Journal of Clinical Investigation

Volumn 108, Issue 1, 2001, Pages 51-62

  Wigginton, J M ^a   Gruys, E ^a   Geiselhart, L ^a   Subleski, J ^a   Komschlies, K L ^a   Park, J W ^a   Wiltrout, T A ^a   Nagashima, K ^a   Back, T C ^a   Wiltrout, R H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG PULSE THERAPY; ENDOTHELIUM CELL; KIDNEY CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FAS LIGAND PROTEIN; INJECTIONS, INTRAPERITONEAL; INTERFERON TYPE II; INTERLEUKIN-12; KIDNEY NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, KNOCKOUT; MICE, MUTANT STRAINS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEPHRECTOMY; RECOMBINANT PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 0034946808     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200110128     Document Type: Article

References (48)

1. Interleukin-12: A cytokine at the interface of inflammation and immunity
2. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
3. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production
4. Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro
5. Induction of interferon gamma production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers
6. Natural killer (NK) cell stimulatory factor or IL12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells
7. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: Implications for the antitumor activity of interleukin 12 and/or interleukin 2
8. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin- 12
9. Interleukins 2 and 12 activate natural killer cytolytic responses of peripheral blood mononuclear cells from patients with head and neck squamous cell carcinoma
10. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts
11. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells
12. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma
13. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: Induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis
14. Interleukin- 12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes
15. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
16. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response
17. Phase I studies of recombinant interferon-gamma
18. Immunotherapy of a murine renal cancer
19. Biological activity of recombinant human interleukin-2 produced in Escherichia coli
20. Site-specific mutagenesis of the human interleukin-2 gene: Structure-function analysis of the cysteine residues
21. Primary hepatocytes from mice treated with IL2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN- gamma (Mig) and chemokine responsive to gamma-2 (Crg-2)
22. Regulation of local host-mediated anti-tumor mechanisms by cytokines: Direct and indirect effects on leukocyte recruitment and angiogenesis
23. IL-12 receptor. II. Distribution and regulation of receptor expression
24. Biology of the interleukin-2 receptor
25. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: Differential use of Janus family tyrosine kinases by IL-2 and IL-12
26. Inhibition of angiogenesis in vivo by interleukin 12
27. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
28. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
29. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor super family, in normal and neoplastic cells
30. Expression of the Fas ligand in cells of T cell lineage
31. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines
32. Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells
33. Fas-signaling and effects on receptor tyrosine kinase signal transduction in human breast epithelial cells
34. IFN-γ-dependent delay of in vivo tumor progression by Fas-overexpression on murine renal cancer cells
35. A role for CD95 ligand in preventing graft rejection
36. Fas ligand-induced apoptosis as a mechanism of immune privilege
37. Fas-mediated cytotoxicity by freshly isolated natural killer cells
38. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion?
39. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
40. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
41. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
42. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand
43. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity
44. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
45. Fas expression and function in normal and malignant breast cell lines
46. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand
47. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12
48. + lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells